

EHA 2024 Congress

June 13–16, 2024
Madrid, Spain



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Hybrid Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

EHA 2024: Top abstracts in ALL

June 13–16, 2024

Frontline and emerging therapies for ALL	
Abstract	Title
S111 View	Blinatumomab for first line treatment in intermediate and high risk Down Syndrome B-cell acute lymphoblastic leukaemia: Initial findings from the ALLTOGETHER1 DS TRIAL
S112 View	Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL – Final results of the ALLG ALL09 “SUBLIME” STUDY
S113 View	Blinatumomab added to prephase and consolidation therapy in adult B-ALL: A comparison of the consecutive HOVON-100 AND H-146 studies
S115 View	Ponatinib versus imatinib in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in the phase 3 PHALLCON trial: In depth responder analysis
P397 View	Augmented use of L-asparaginase markedly improves the treatment result of AYA ALL patients: Result of prospective MRD 2014 study conducted by Fukuoka Blood And Marrow Transplantation Group (FBMTG)
P398 View	Ponatinib, chemotherapy and transplantation for newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Final results of the Phase 2 PONALFIL trial
P400 View	Busulfan plus cyclophosphamide vs. Total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia
P407 View	Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/ lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest from AALL1931
P409 View	Blinatumomab induction therapy following reduced-dose chemotherapy in newly diagnosed adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: Multicentre, single arm, Phase 2 study
P411 View	A full pediatric regimen for adult patients with Philadelphia negative acute lymphoblastic leukemia achieves excellent outcomes with acceptable toxicity
P416 View	Blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL): Safety run-in follow-up for the phase 3 GOLDEN GATE study.
P427 View	Combination of third generation TKI olverembatinib and chemotherapy or blinatumomab for new diagnosed adult Ph+ ALL patients
P1740 View	Improving outcome in elderly Philadelphia negative acute lymphoblastic leukemia: Feasibility and efficacy of an intensive PEG-asparaginase-based regimen

Treatments for relapsed/refractory ALL

Abstract	Title
S110 View	WU-CART-007, an allogeneic CAR-T cell targeting CD7, is highly effective against relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)
S114 View	Obecabtagene autoleucl in adult relapsed/refractory B-cell acute lymphoblastic leukemia: Survival and potential impact of CAR T-cell persistence and stem cell transplantation in the FELIX Study
P395 View	Subsequent allotransplant in adults with advanced acute lymphoblastic leukemia after CD19 CAR T-cell therapy: A multi-center randomized controlled trial
P402 View	Efficacy and tolerance of modified HyperCVAD, blinatumomab, and TKI, combination as a treatment for relapsed or refractory Ph+ B-cell acute lymphoblastic leukemia
P429 View	Five-year outcome of CD19 combined with CD22 CAR T-cell therapy in B-ALL patients relapsed after allo-transplantation

Biomarkers, prognosis, and biology

Abstract	Title
S116 View	Early response refines end of induction measurable residual disease stratification in T-cell acute lymphoblastic leukaemia
P403 View	MRD monitoring in childhood Ph-positive acute lymphoblastic leukemia: Prognostic significance and correlation between multiparameter flow cytometry and RT-QPCR
P419 View	Impact of NGS MRD and clonal evolution on clinical prognosis in pediatric Ph+ ALL patients
P368 View	The genomic landscape of relapsed infant and childhood KNT2A-rearranged acute leukemia

Real-world outcomes

Abstract	Title
P413 View	Brexucabtagene autoleucl (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia with marrow blasts <5%, including patients (pts) with NGS MRD negative disease
P424 View	Real-world utilization of blinatumomab in adult and pediatric patients with acute lymphoblastic leukemia in France: Results from the ATHENA study



EHA 2024

Follow us on X to keep up to date
with the latest from the congress

@ALL_Hub_

#EHA2024

View all @ALL_Hub_ tweets from #EHA2024



Brought to you by

